Навигация
Архив выставки новых поступлений | Отечественные поступления | Иностранные поступления | Сиглы
ОбложкаPredictive ADMET: integrative approaches in drug discovery and development / ed. by J.Wang, L.Urban. - Hoboken: Wiley, 2014. - xiv, 596 p., [6] l. of plates: ill., tab. - Incl. bibl. ref. - Ind.: p.583-596. - ISBN 978-1-118-29992-0
Шифр: (И/Р28-P91) 02
 

Место хранения: 02 | Отделение ГПНТБ СО РАН | Новосибирск

Оглавление / Contents
 
PREFACE ........................................................ ix
CONTRIBUTORS ................................................... xi

I  INTRODUCTION TO THE CURRENT SCIENTIFIC, CLINICAL, AND 
   SOCIAL ENVIRONMENT OF DRUG DISCOVERY AND DEVELOPMENT
1  Current Social, Clinical, and Scientific Environment of
   Pharmaceutical R&D ........................................... 3
   Laszlo Urban, Jean-Pierre Valentin, Kenneth I. Kaitin, and 
   Jianling Wang
2  Polypharmacology and Adverse Bioactivity Profiles Predict
   Potential Toxicity and Drug-related ADRs .................... 23
   Teresa Kaserer, Veronika Temml, and Daniela Schuster

II INTELLIGENT INTEGRATION AND EXTRAPOLATION OF ADMET DATA
3  ADMET Diagnosis Models ...................................... 49
   Bernard Falle, Suzanne Skolnik, and Jianling Wang
4  PATH (Probe ADME and Test Hypotheses): A Useful Approach
   Enabling Hypothesis-driven ADME Optimization ................ 63
   Leslie Bell, Suzanne Skolnik, and Dallas Bednarczyk
5  PK-MATRIX—A Permeability: Intrinsic Clearance System for
   Prediction, Classification, and Profiling of 
   Pharmacokinetics and Drug-drug Interactions ................. 89
   Urban Fagerholm
6  Maximizing the Power of a Local Model for ADMET-property 
   Prediction ................................................. 103
   Sebastien Ronseaux, Jeremy Beck, and Clayton Springer
7  Chemoinformatic and Chemogenomic Approach to ADMET ......... 125
   Virginie Y. Martiny, Ilza Pajeva, Michael Wiese, Andrew 
   M. Davis, and Maria A. Miteva
8  Multiparameter Optimization of ADMET for Drug Design ....... 145
   Matthew D. Segall and Edmund J. Champness
9  PBPK: Integrating In Vitro and In Silico Data in 
   Physiologically Based Models ............................... 167
   Hannah M. Jones and Neil Parrott
10 Emerging Full Mechanistic Physiologically Based Modeling ... 189
   Kiyohiko Sugano
11 Pharmacokinetic/Pharmacodynamic Modeling in Drug
   Discovery: A Translationai Tool to Optimize Discovery 
   Compounds Toward the Ideal Target-specific Profile ......... 211
   Patricia Schroeder

III ASSESSMENT AND MITIGATION OF CRITICAL CLINICALLY RELEVANT
    ADMET RISKS IN DRUG DISCOVERY AND DEVELOPMENT
12 In Vitro-ln Silico Tools to Predict Pharmacokinetics
   of Poorly Soluble Drug Compounds ........................... 235
   Christian Wagner and Jennifer B. Dressman
13 Evaluation of the Collective Impact of Passive 
   Permeability and Active Transport on In Vivo Blood-brain 
   Barrier and Gastrointestinal Drug Absorption ............... 263
   Donna A. Volpe, Hong Shen, and Praveen V. Balimane
14 Integrated Assessment of Drug Clearance and Cross-Species
   Scalability ................................................ 291
   Kevin Beaumont, James R. Gosset, and Chris E. Keefer
15 Practical Anticipation of Human Efficacious Doses and 
   Pharmacokinetics using Preclinical In Vitro and In Vivo
   Data ....................................................... 319
   Tycho Heimbach, Rakesh Gollen, and Handan He
16 Management and Mitigation of Human Drug-drug Interaction
   Risks in the Drug Discovery and Development Phases ......... 353
   Heidi J. Einolf and Imad Hanna
17 Integrated Assessment and Clinical Translation of In 
   Vitro Off-target Safety Pharmacology Risks ................. 397
   Patrick Y. Muller and Christian F. Trendelenburg
18 Integrated Risk Assessment of Cardiovascular Safety in 
   Drug Discovery ............................................. 407
   Gül Erdemli and Ruth L. Martin
19 Drug-induced Hepatotoxicity: Advances in Preclinical 
   Predictive Strategies and Tools ............................ 433
   Donna M. Dambach
20 Carcinogenicity and Teratogenicity Assessment .............. 467
   Hans-Jörg Martus, David Bechnan, and Lutz Mueller
21 Nephrotoxicity: Development of Biomarkers for Preclinical
   and Clinical Application ................................... 491
   Frank Dieterle and Estelle Marrer

IV SUCCESS STORIES AND LESSONS LEARNED
22 Early Intervention with Formulation Strategies for 
   Multidimensional Problems to Optimize for Success .......... 507
   Stephanie Dodd, Christina Capacci-Daniel, Christopher
   Towler, Riccardo Panicucci, and Keith Hoffmaster
23 Cytochrome P450-mediated Drug Interaction and 
   Cardiovascular Safety: The Seldane to Allegra 
   Transformation ............................................. 523
   F. Peter Guengerich
24 Clinical Toxicity Profile of VEGF Inhibitors ............... 535
   Mark P.S. Sie and Ferry A.L.M. Eskens
25 Cardiomyopathy: Drug Induced and Predisposed ............... 555
   Shirley A. Aguirre and Eileen R. Blasi
26 Safety Management by Pharmacokinetic Considerations:
   Ranibizumab (Lucentis) and Bevacizumab (Avastin) ........... 569
   Nicole H. Siegel and Manju L. Subramanian

INDEX ......................................................... 583

Архив выставки новых поступлений | Отечественные поступления | Иностранные поступления | Сиглы
 

[О библиотеке | Академгородок | Новости | Выставки | Ресурсы | Библиография | Партнеры | ИнфоЛоция | Поиск | English]
  Пожелания и письма: www@prometeus.nsc.ru
© 1997-2017 Отделение ГПНТБ СО РАН (Новосибирск)
Статистика доступов: архив | текущая статистика
 

Документ изменен: [an error occurred while processing this directive]. Размер: [an error occurred while processing this directive] bytes.
Посещение N 190 c 14.06.2016